Sharps Technology Inc
Sharps Technology Inc provides medical equipment, supplies, and distribution services within the healthcare sector, primarily generating revenue through the sale and distribution of medical products.
Business. Sharps Technology Inc (STSS.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Sharps Technology is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sharps Technology Inc (STSS.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Sharps Technology is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Sharps Technology Inc has a market capitalization of $77.3 million and a price-to-book ratio of 11.27, indicating a premium valuation relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, its liquidity position is rated as low, and it has a current ratio of 1.15, indicating limited short-term liquidity cushion.
The company's profitability metrics are negative, with a return on equity of -14.32% and a return on assets of -10.02%. These figures are below the industry norms for medical equipment and supplies firms, which typically exhibit positive returns on equity and assets. The operating and net losses of $1.84 million and $0.98 million, respectively, further underscore the company's unprofitable operations.
Sharps Technology Inc's revenue is not disclosed in the latest financials, but the most recent actual revenue reported by analysts is $7.01 million. The company does not provide segment or geographic breakdowns in the available data, making it difficult to assess revenue concentration or geographic exposure. Without segment data, it is unclear whether the company is diversified or reliant on a single product line or region.
The company's growth trajectory is uncertain, as the latest financials show a net loss and negative operating cash flow of $1.89 million. Analysts have not provided forward-looking revenue estimates, and the absence of revenue growth data makes it difficult to project future performance. The company's capital expenditures are minimal, with only $2,850 spent in the latest period, suggesting limited investment in growth or operational expansion.
Risk factors for Sharps Technology Inc include its unprofitable operations and negative cash flows, which could impact its ability to sustain operations without external financing. The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is rated as low. However, the absence of long-term debt does not eliminate the possibility of future financing needs, which could lead to equity dilution or increased leverage.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The most recent actual revenue reported by analysts is $7.01 million, but there are no recent earnings calls, transcripts, or 10-K filings provided in the data to assess management commentary or strategic direction.
- Sharps Technology Inc is unprofitable, with a return on equity of -14.32% and a return on assets of -10.02%.
- The company has a high price-to-book ratio of 11.27, indicating a premium valuation despite negative earnings.
- Sharps Technology Inc has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure.
- The company's liquidity position is rated as low, with a current ratio of 1.15.
- No immediate filing-based liquidity or dilution flags were detected, and dilution risk is rated as low.
- The company's growth trajectory is unclear due to the absence of revenue growth data and forward-looking guidance.
Bull / Bear case
Generated · model-assistedSharps Technology maintains a strong current ratio of 4.02, indicating robust short-term liquidity to meet immediate obligations.
The company carries minimal leverage with a debt-to-equity ratio of 0.02, reducing financial risk compared to peers.
Sharps Technology generated gross profit of $6.4 million in fiscal 2026, demonstrating initial revenue generation capability.
Operating losses improved significantly from fiscal 2024 to 2025, narrowing from $10.1 million to $5.6 million.
Cash conversion metrics rank in the top quartile relative to the medical equipment cohort median.
Net income plummeted to a massive loss of $282.5 million in fiscal 2026, signaling severe profitability deterioration.
Free cash flow turned deeply negative at -$270.2 million in fiscal 2026, indicating significant cash burn.
In focus — financials by report
Revenue $4.5M; Operating income −76 271,7% YoY.
- ▍Revenue $4.5M
- ▍Operating income −76 271,7% YoY
- ▍Net income −3 935,3% YoY
- ▍Free cash flow −64 443,1% YoY
- ▍Net margin -4061.4%
Revenue $222.7k; Operating income −56,5% YoY.
- ▍Revenue $222.7k
- ▍Operating income −56,5% YoY
- ▍Net income +269,3% YoY
- ▍Free cash flow +195,1% YoY
- ▍Net margin 1598.1%
Revenue $0.00; Operating income $212.8k.
- ▍Revenue $0.00
- ▍Operating income $212.8k
Revenue $0.00; Operating income -$2.0M.
- ▍Revenue $0.00
- ▍Operating income -$2.0M
Revenue $0.00; Operating income -$1.9M.
- ▍Revenue $0.00
- ▍Operating income -$1.9M
Revenue $0.00; Operating income -$1.8M.
- ▍Revenue $0.00
- ▍Operating income -$1.8M
Revenue $7.0M; Operating income −4 744,7% YoY.
- ▍Revenue $7.0M
- ▍Operating income −4 744,7% YoY
- ▍Net income −2 938,9% YoY
- ▍Free cash flow −5 585,3% YoY
- ▍Net margin -4030.5%
Revenue $0.00; Operating income +45,0% YoY.
- ▍Revenue $0.00
- ▍Operating income +45,0% YoY
- ▍Net income +5,5% YoY
- ▍Free cash flow +50,7% YoY
Revenue $0.00; Operating income −15,9% YoY.
- ▍Revenue $0.00
- ▍Operating income −15,9% YoY
- ▍Net income −112,1% YoY
- ▍Free cash flow −35,8% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Return On Equitynet_income / total_equity
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Sharps Technology Inc Market data — financials · 2026-05-29
- Sharps Technology Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Gross margin (FY 2025-12-31): -202.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -106.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -105.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.02xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.02xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -62.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -11.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -149.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 3,579.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 13,144.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,275.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -4,744.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 99.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 99.5%Derived (calculated)
- Net margin (FY 2025-12-31): -138,400.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -2,938.9%Derived (calculated)
- Total assets (annual): USD 269.08MSEC XBRL filing
- Cost of revenue (annual): USD 617.45KSEC XBRL filing
- Pre-tax income (annual): USD -270.34MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -11SEC XBRL filing
- R&D expense (annual): USD 198.76KSEC XBRL filing
- Gross profit (annual): USD -413.32KSEC XBRL filing
- Cash & equivalents (annual): USD 10.38MSEC XBRL filing
- Shareholders' equity (annual): USD 264.38MSEC XBRL filing